NARI operates the only 30 MeV medium-sized cyclotron in Taiwan that is capable of producing I-123. The cyclotron can produce a variety of medical radioisotopes and the PIC/S GMP-certified Radiopharmaceutical Production Center develops and produces radiopharmaceuticals for clinical diagnosis and treatment use. Radioactive iodine labeling technology was developed by the NARI to create Taiwan’s first I-123 MIBG injection. A computer-controlled synthesis system with automatic or semi-automatic control was also developed to improve the consistency of product quality and produce high-quality radiopharmaceuticals for clinical use. The synthesis system is now patented in the ROC, Japan, and the US. The synthesis system was also used by the NARI to establish chemistry, manufacturing, and control technical (CMC) documentation and apply for pharmaceutical registration. Pharmaceutical registration for the "INER MIBG Injection" was approved in 2019 (MOHW-PM-R00037). To increase the shelf-life of drug to meet the needs of hospitals in central and southern Taiwan, restocking inspection, process testing, and personnel training were carried out before three consecutive batches of "INER MIBG Injection" were produced and tested for efficacy/stability. All quality assurance requirements were met so the MOHW approved an extension of the shelf-life to 10 hours in 2022 and the injection is now routinely supplied to hospitals for clinical trials on request.